公开(公告)号：US20240041855A1

公开(公告)日：2024-02-08

申请号：US18491871

申请日：2023-10-23

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Daniella LICHT ,  Ioana Lovinger ,  Laura Yehudit Guilatt ,  Merav Bassan

IPC: A61K31/451 ,  A61K9/16 ,  A61K9/20

CPC classification number: A61K31/451 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2068

Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.

公开(公告)号：US11452694B2

公开(公告)日：2022-09-27

申请号：US16803145

申请日：2020-02-27

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Danit Licht ,  Ioana Lovinger

IPC: A61K31/451 ,  A61K9/20 ,  A61K9/48

Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.